Merger Notes From the BIO Investor Forum

Notes from David Thomas who is out in San Francisco at the BIO Investor Forum,

Reverse mergers: It is difficult for a shell in this market climate to take on quality biotechs due to disagreements on valuation of the VCs vs. public company boards. Other issues with doing reverse mergers are disagreements with fitting the [...]

Productive Partnerships in Biomedical Translational Medicine

From one of my colleagues, Joseph Colangelo at the BIO Investor Forum,
“The university, financing and industry communities have gathered to discuss some of the core issues involved in developing and commercializing early stage technologies. Improving the relationship between the stakeholders in translational research can go a long way to helping each side understand the [...]

Epilepsy Facts From the BIO Investor Forum

Epilepsy is a neurological disorder characterized by hyper-synchronous electrical discharge in the brain. The disease affects approximately 1% of the U.S. population (3 million) with a slightly higher 1-2% worldwide incidence due to less consistent prenatal care. The incidence is also expected to increase in the U.S. due to the aging population.
The current [...]

Capital Access 201 – BIO Investor Forum Kicks Off

Moments ago, panelists at the opening plenary painted a startlingly realistic picture of the industry, but emphasized that this is the time for companies to be more aggressive and strategic in how they target and approach potential investors and partners. Moderator Ben Perkins, PhD, initiated a lively discussion focused on how the realities of the [...]

Success, Maybe, I think …

Communicating science can be tough. There are some pretty complex concepts, ideas, problems, and success stories to get across to the public, media, and politicians. I’m not talking about what a journalist or broadcaster has to do to get the message  across. I’m talking about people like me. PR folks (go ahead and call us flacks – I [...]

40% More Investors Expected for BIF

Despite the market downturn, BIO is expecting a substantial increase in anticipated investor participation in the Seventh Annual BIO Investor Forum, taking place Oct. 29-31 in San Francisco, Calif. at the Palace Hotel.
More than 240 venture capital and public market investors are expected to attend – representing a 40 percent increase in participation compared to [...]

Plenary and Business Panels to Address Growing Challenges of Small Biotech Companies at the BIO Investor Forum

Plenary sessions and roundtables will address how small biotech companies can continue to innovate and grow despite current market conditions.
The BIO Investor Forum’s plenary sessions and business roundtables will focus on economic and business issues facing the biotech industry, including M&A, capital access, exit strategies, technology transfer, and outsourcing among other topics. Featured plenary [...]

This week’s Top Biotech Bioethics News: Pfizer’s stem cell ventures, Eli Lilly’s DR payment disclosures, & Supreme Court Case Wyeth v. Levine’s Preemption Temptation

Pfizer and Eli Lilly have been noteworthy with respect to their efforts to produce responsible innovations this week.  Pfizer is advancing responsible stem cell research by currently focusing on induced pluripotent stem cells (iPs) and Eli Lilly is setting a great example regarding industry disclosures and increased transparency.

Medical News Today reports, Pfizer, the world’s largest drug company, is getting [...]